Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.

The British journal of dermatology - 1 Feb 2004

Quaglino P, Fierro M T, Rossotto G L, Savoia P, Bernengo M G

Abstract excerpt

BACKGROUND: Purine analogues [fludarabine monophosphate (FAMP); deoxycoformycin and 2-chlorodeoxyadenosine) and extracorporeal photochemotherapy (ECP) have been suggested to be active agents in advanced cutaneous T-cell lymphoma (CTCL) patients. OBJECTIVES: To explore further the clinical efficacy and safety of FAMP monochemotherapy in advanced CTCL and to evaluate if the sequential association of ECP to FAMP in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lymphocyte Subsets

Share to Mycosis Fungoides

Share to Pilot Projects

Share to Skin Neoplasms

Share to Survival Analysis

Share to Treatment Outcome

Source

Identifiers

PMID: 14996105
DOI: 10.1111/j.1365-2133.2004.05712.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.PMID 14996105Read ↗

Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis.Semantic proximity Read ↗

Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.Semantic proximity Read ↗

Oncolytic effect of SARS-CoV-2 in a patient with mycosis fungoides (MF): a case reportSemantic proximity Read ↗

[Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].Semantic proximity Read ↗

Peripheral blood involvement in a mycosis fungoides patient with limited skin lesions: phenotypical features and homing molecule pattern.Semantic proximity Read ↗

Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: Search for recurrent chromosome abnormalitiesSemantic proximity Read ↗

Reversible resistance to apoptosis in cutaneous T cell lymphoma.Semantic proximity Read ↗

HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma.Semantic proximity Read ↗

Methotrexate and PralatrexateSemantic proximity Read ↗

Cutaneous T cell lymphoma differing from classical mycosis fungoides and Sézary syndrome: clinical, histological and immunohistochemical studies of six cases.Semantic proximity Read ↗

Recurring Structural Chromosome Abnormalities in Peripheral Blood Lymphocytes of Patients With Mycosis Fungoides/Sezary SyndromeSemantic proximity Read ↗

Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.